uniQure NV
Slēgts
49.16 11.52
Pārskats
Akcijas cenas izmaiņa
24h
Min
44.17
Max
49.51
Ienākumi | -16M -54M |
|---|---|
Pārdošana | -2M 3.6M |
EPS | -0.73 |
Peļņas marža | -1,502.948 |
Darbinieki | 221 |
EBITDA | 13M -36M |
Rekomendācijas | Pirkt (spēcīgs) |
|---|---|
Prognoze 12 mēnešiem | +33.66% upside |
Nākamie ieņēmumi | 2026. g. 28. jūl. |
|---|
Tirgus kapitalizācija | 454M 1.8B |
|---|---|
Iepriekšējā atvēršanas cena | 37.64 |
Iepriekšējā slēgšanas cena | 49.16 |
uniQure NV Grafiks
Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.
Par uniQure NV
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
